Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860227 | 0.78 | P2RX7 (1.00) | P2RX7LMNAMAPTMAPK1 | |
| SCHEMBL6939824 | 0.76 | P2RX7 (0.71) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL7930528 | 0.74 | P2RX7 (0.59) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL31554508 | 0.74 | P2RX7 (0.59) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL6939799 | 0.74 | P2RX7 (0.59) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL6941775 | 0.74 | P2RX7 (0.74) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL9095943 | 0.73 | POLB (0.64) | P2RX7ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL9095157 | 0.72 | ALDH1A1 (0.61) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL6943094 | 0.72 | P2RX7 (0.78) | P2RX7ALDH1A1LMNAGAAMAPT | |
| SCHEMBL3704664 | 0.72 | GAA (0.61) | P2RX7ALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | claimed |
| JP-2007501782-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654217-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | claimed |
| WO-2005014529-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | claimed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1654217-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014529-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | P2RX2, P2RX3, P2RX7 | P2RX7 3/4885ALDH1A1 2254/4885LMNA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.